Reviews of Science for Science Librarians: Chemobrain

被引：0
作者：
Stankus T. [1 ]
机构：
[1] Health Sciences, University of Arkansas Libraries, Fayetteville, AR
来源：
Science and Technology Libraries | 2021年 / 40卷 / 04期
关键词：
chemofog; Chemotherapy side effects; cognitive deficits; executive function; memory impairment;
D O I：
10.1080/0194262X.2021.1982841
中图分类号：
学科分类号：
摘要：
According to the Centers for Disease Control and Prevention each year about 650,000 Americans with cancer undergo potentially lifesaving treatments usually via some combination of chemotherapeutic agents, adjuvants, or hormones. Over one hundred thousand of these patients are likely subsequently to experience difficulties with concentration and memory. These deficits may last for several months or persist for years. This paper surveys key components of the chemobrain story: Demographics; deficits, drugs, coping strategies, and the possibilities for recovery. © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
引用
收藏
页码：341 / 357
页数：16
相关论文
共 106 条
  • [1] Aaldriks A., Maartense E., Nortier H.J.W.R., Lydia G.M., van der Geest, le Cessie S., Tanis B.C., Portielje J.E.A., Ypma P., Giltay E.J., Prognostic factors for the feasibility of chemotherapy and the geriatric prognostic index (GPI) as risk profile for mortality before chemotherapy in the elderly, Acta Oncologica (Stockholm, Sweden), 55, 1, pp. 15-23, (2016)
  • [2] Ahles T.A., Saykin A.J., Noll W.W., Furstenberg C.T., Guerin S., Cole B., Mott L.A., The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy, Psycho-Oncology, 12, 6, pp. 612-619, (2003)
  • [3] Allegra A., Innao V., Basile G., Pugliese M., Allegra A.G., Pulvirenti N., Musolino C., Post-chemotherapy cognitive impairment in hematological patients: Current understanding of chemobrain in hematology, Expert Review of Hematology, 13, pp. 393-404, (2020)
  • [4] Cancer treatment & survivorship facts & figures 2019–2021, (2019)
  • [5] Survival rates for breast cancer. SEER= Surveillance, epidemiology, and end results, (2021)
  • [6] Cyclophosphamide, (2021)
  • [7] Anderson D.E., Kedar S., Bhatt V.R., Schmid K., Holstein S.A., Rizzo M., Neurophysiologic and ophthalmic markers of chemotherapy-related cognitive impairment in patients diagnosed with hematologic cancer: A feasibility study, Journal of the Neurological Sciences, 410, March, (2020)
  • [8] Andreotti C., Root J.C., Ahles T.A., McEwen B.S., Compas B.E., Cancer, coping, and cognition: A model for the role of stress reactivity in cancer-related cognitive decline, Psycho-Oncology, 24, 6, pp. 617-623, (2015)
  • [9] Andrykowski M.A., Burris J.L., Walsh E., Small B.J., Jacobsen P.B., Attitudes toward information about genetic risk for cognitive impairment after cancer chemotherapy: Breast cancer survivors compared with healthy controls, Journal of Clinical Oncology, 28, 21, pp. 3442-3447, (2010)
  • [10] Andryszak P., Wilkosc M., Zurawski B., Izdebski P., Verbal fluency in breast cancer patients treated with chemotherapy, Breast Cancer (Tokyo, Japan), 24, 3, pp. 376-383, (2017)
12345678910